GlassScriptPhysician profile
Sarah E Salamon
NPI 1790103646
$502.20
in general payments reported to CMS, 2019-2025
13 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.14 · 2020: $23.14 · 2021: $48.54 · 2022: $85.11 · 2023: $143 · 2024: $73.01 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.24 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $59.51 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $41.95 | 2023-2025 | |
| Coopersurgical, INC. | $39.44 | 2022-2023 | Paragard T 380a |
| Pfizer INC. | $34.19 | 2023-2025 | |
| Dexcom, INC. | $26.49 | 2023 | Dexcom G6 Transmitter |
| Optumhealth Care Solutions, LLC | $23.81 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Organon LLC | $23.68 | 2024 | |
| Smith+Nephew, INC. | $23.67 | 2022 | |
| Bausch Health US, LLC | $19.37 | 2024 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $16.89 | 2025 | Gardasil 9 |
| Exeltis, USA INC. | $15.95 | 2024 | Slynd |
| Mayne Pharma Commercial LLC | $14.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Salamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.